Axsome Therapeutics saw a welcome improvement to its Relative Strength (RS) Rating on Friday, rising from 67 to 73.
This unique rating tracks market leadership by using a 1 (worst) to 99 (best) score that shows how a stock's price action over the trailing 52 weeks compares to other publicly traded companies.
Decades of market research reveals that the market's biggest winners often have an RS Rating of above 80 in the early stages of their moves. See if Axsome Therapeutics can continue to rebound and hit that benchmark.
How To Invest In Stocks In Both Bull And Bear Markets
Axsome Therapeutics is working on a cup with handle with a 97.00 buy point. See if the stock can clear the breakout price in heavy trade.
The company showed 0% earnings growth in its most recent report. Sales rose 87%. The company is expected to report its latest numbers on or around Nov. 12.
Axsome Therapeutics holds the No. 190 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Exelixis and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
